Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kronos Bio (KRON)
NASDAQ:KRON
Kronos Bio (KRON) Stock Price & Analysis
180 Followers
KRON Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.69 - $2.22
Previous Close$1.25
Volume128.95K
Average Volume (3M)536.49K
Market Cap
$75.12M
Enterprise Value-$49.39M
Total Cash (Recent Filing)$151.98M
Total Debt (Recent Filing)$27.47M
Price to Earnings (P/E)―
Beta2.07
Next Earnings
Aug 07, 2024EPS Estimate
-$0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding60,094,409
10 Day Avg. Volume1,042,386
30 Day Avg. Volume536,485
Standard Deviation0.18
R-Squared0.23
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)0.47
Price to Sales (P/S)28.39
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-6.48
Enterprise Value/Gross Profit-7.85
Enterprise Value/Ebitda0.46
Forecast
1Y Price Target
$4.13Price Target Upside230.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Kronos Bio News
PremiumCompany Announcements
Kronos Bio’s Restructuring Risks: Cost Cuts Versus Operational EfficiencyBulls Say, Bears Say
Bulls Say
Clinical Trial ProgressIncreased efficacy is expected with KB-0742 treatment during the Phase I/II trial update.
Financial PerformanceKronos recorded a 4Q23 net loss of $0.43 per share, narrower than the prior net loss estimate of $0.53 per share, predominantly driven by lower-than-anticipated operating expenses.
New Drug DevelopmentKronos has unveiled KB-9558, a potential new therapy for multiple myeloma, with IND-enabling studies set to complete this year.
Bears Say
Clinical DataNegative clinical data with other candidates.
Clinical TrialsKronos will not continue into the Phase II portion of the Phase I/II trial of lanraplenib due to lack of complete responses in evaluable patients.
Regulatory ApprovalInability to obtain regulatory approval for KB-0742.
---
Ownership Overview
57.41% Insiders
13.89% Mutual Funds
7.91% Other Institutional Investors
20.80% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KRON FAQ
What was Kronos Bio’s price range in the past 12 months?
Kronos Bio lowest stock price was $0.69 and its highest was $2.22 in the past 12 months.
What is Kronos Bio’s market cap?
Currently, no data Available
When is Kronos Bio’s upcoming earnings report date?
Kronos Bio’s upcoming earnings report date is Aug 07, 2024 which is in 15 days.
How were Kronos Bio’s earnings last quarter?
Kronos Bio released its earnings results on May 09, 2024. The company reported -$0.5 earnings per share for the quarter, missing the consensus estimate of -$0.422 by -$0.078.
Is Kronos Bio overvalued?
According to Wall Street analysts Kronos Bio’s price is currently Undervalued.
Does Kronos Bio pay dividends?
Kronos Bio does not currently pay dividends.
What is Kronos Bio’s EPS estimate?
Kronos Bio’s EPS estimate is -$0.36.
How many shares outstanding does Kronos Bio have?
Kronos Bio has 60,094,410 shares outstanding.
What happened to Kronos Bio’s price movement after its last earnings report?
Kronos Bio reported an EPS of -$0.5 in its last earnings report, missing expectations of -$0.422. Following the earnings report the stock price went down -2.857%.
Which hedge fund is a major shareholder of Kronos Bio?
Among the largest hedge funds holding Kronos Bio’s share is Wildcat Capital Management, Llc. It holds Kronos Bio’s shares valued at 2M.
---
Kronos Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.13 (230.40% Upside)
$4.13 (230.40% Upside)
Blogger Sentiment
Bullish
KRON Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 4.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.43%
12-Months-Change
Fundamentals
Return on Equity
-64.20%
Trailing 12-Months
Asset Growth
-36.69%
Trailing 12-Months
Company Description
Kronos Bio
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription.
---
KRON Stock 12 Month Forecast
Average Price Target
$4.13
▲(230.40% Upside)
Technical Analysis
Best Analysts Covering KRON
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-34.68%
reiterated a buy rating 3 months ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -34.68% per trade.
---